Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Lymphatic Metastasis × Ipilimumab × Clear all

Phase

Status

Withdrawn 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 13 Uterine Cervical Neoplasms 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Hematologic Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Xeroderma Pigmentosum 1 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uveal Melanoma 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1 Solid Tumor 1 Sarcoma 1 Neuroblastoma 1 Multiple Myeloma 1 Lymphoma 1 Lymphatic Metastasis 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hemangiosarcoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms, Hereditary Nonpolyposis 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Merkel Cell 1 Carcinoma 1 Breast Neoplasms 1

Interventions

Nivolumab 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05504642 2023-04-18

CERAD-IMMUNE

Universitätsklinikum Köln

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡